康美药业
(600518)
| 流通市值：214.25亿 | | | 总市值：214.35亿 |
| 流通股本：138.22亿 | | | 总股本：138.29亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,079,786,637.44 | 5,252,215,058.26 | 3,959,603,514.66 | 2,577,397,097.25 |
| 营业收入 | 1,079,786,637.44 | 5,252,215,058.26 | 3,959,603,514.66 | 2,577,397,097.25 |
| 二、营业总成本 | 1,098,903,388.14 | 5,360,814,274.25 | 4,028,487,323.58 | 2,612,345,435.82 |
| 营业成本 | 841,450,632.21 | 4,203,085,987.14 | 3,204,602,637.88 | 2,091,882,757.44 |
| 税金及附加 | 11,397,756.22 | 63,416,875.37 | 37,110,255.98 | 22,958,613.77 |
| 销售费用 | 115,900,980.93 | 526,397,113.15 | 385,739,589.26 | 241,966,448.24 |
| 管理费用 | 121,162,604.93 | 512,744,622.3 | 367,816,518.44 | 237,175,089.14 |
| 研发费用 | 9,657,160.81 | 45,330,399.34 | 32,691,882.64 | 17,912,407.27 |
| 财务费用 | -665,746.96 | 9,839,276.95 | 526,439.38 | 450,119.96 |
| 其中:利息费用 | 1,282,816.77 | 18,665,633.43 | 4,944,162.84 | 3,128,868.69 |
| 其中:利息收入 | 2,443,440.16 | 10,501,391.58 | 5,576,587.76 | 3,366,514.32 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -4,210.83 | 6,681.98 | 10,438.11 | -919.26 |
| 加:投资收益 | 2,175,106.78 | 90,603,779.48 | 27,367,448.37 | 231,879.41 |
| 资产处置收益 | 34,099.99 | 846,811.6 | 2,038,103.48 | 286,015.92 |
| 资产减值损失(新) | -741,917.15 | -184,382,843.48 | -798,496.74 | -798,690.5 |
| 信用减值损失(新) | -4,517,098.47 | 26,093,191.07 | 39,160,071.24 | 42,034,577.77 |
| 其他收益 | 8,839,534.29 | 210,442,695.17 | 32,838,029.09 | 22,800,164.59 |
| 四、营业利润 | -13,331,236.09 | 35,011,099.83 | 31,731,784.63 | 29,604,689.36 |
| 加:营业外收入 | 112,842.36 | 62,009,629.97 | 3,243,803.6 | 606,841.51 |
| 减:营业外支出 | 788,856.69 | 53,904,815.31 | 4,382,544.78 | 1,689,620.99 |
| 五、利润总额 | -14,007,250.42 | 43,115,914.49 | 30,593,043.45 | 28,521,909.88 |
| 减:所得税费用 | 1,973,447.42 | 30,686,744.52 | 15,501,919.69 | 10,206,256 |
| 六、净利润 | -15,980,697.84 | 12,429,169.97 | 15,091,123.76 | 18,315,653.88 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -15,980,697.84 | 12,429,169.97 | 15,091,123.76 | 18,315,653.88 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -16,563,882.39 | 10,327,997.77 | 13,082,309.31 | 16,901,389.86 |
| 少数股东损益 | 583,184.55 | 2,101,172.2 | 2,008,814.45 | 1,414,264.02 |
| 扣除非经常损益后的净利润 | -19,043,853.23 | -294,235,904.21 | -37,936,716.64 | -3,618,595.24 |
| 七、每股收益 | | | | |
| 八、其他综合收益 | -15,805.99 | -80,909.46 | -69,577.23 | -30,319.91 |
| 归属于母公司股东的其他综合收益 | -15,805.99 | -80,909.46 | -69,577.23 | -30,319.91 |
| 九、综合收益总额 | -15,996,503.83 | 12,348,260.51 | 15,021,546.53 | 18,285,333.97 |
| 归属于母公司股东的综合收益总额 | -16,579,688.38 | 10,247,088.31 | 13,012,732.08 | 16,871,069.95 |
| 归属于少数股东的综合收益总额 | 583,184.55 | 2,101,172.2 | 2,008,814.45 | 1,414,264.02 |
| 公告日期 | 2026-04-30 | 2026-04-18 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |